Valion Bio reported finishing an initial evaluation of LarmorBio's platform, but gave no findings or next step. The filing does not show whether the platform could benefit Valion Bio's business.
The filing does not say whether the platform worked, how Valion Bio might use it, or whether it could bring the company business. The completed evaluation is a step, but no findings or next steps are reported.
Follow Valion Bio, Inc. (VBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VBIO